IMMUNOGLOBULINA UMANA NORMALE per somministrazione endovenosa ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
14Chronic inflammatory demyelinating polyneuropathy1

14. Chronic inflammatory demyelinating polyneuropathy


Clinical trials : 167 Drugs : 158 - (DrugBank : 38) / Drug target genes : 13 - Drug target pathways : 23
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2013-005558-31-IT
(EUCTR)
26/01/201520/05/2015Extension of the international study on efficacy and safety of I10E in CIDP patientsInternational, multicentre, efficacy and safety study of I10E in the maintenance treatment of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Extension of PRISM studyI10E-1302 - PRISM 2 Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
MedDRA version: 18.0;Level: PT;Classification code 10057645;Term: Chronic inflammatory demyelinating polyradiculoneuropathy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: : immunoglobulina umana normale 10% per somministrazione endovenosa
Product Code: I10E
INN or Proposed INN: immunoglobulina umana normale per somministrazione endovenosa
Other descriptive name: IMMUNOGLOBULINA UMANA NORMALE per somministrazione endovenosa
LFB BIOTECHNOLOGIESNULLNot RecruitingFemale: yes
Male: yes
30Phase 3France;Morocco;Mexico;Spain;Turkey;Germany;United Kingdom;Italy